A Phase I Trial To Evaluate Safety And Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant In Recipients Of Allogeneic Hematopoietic Stem Cell Transplant
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs CMV-pp65-vaccine-PepVax (Primary) ; PF 3512675
- Indications Cytomegalovirus infections; Graft-versus-host disease
- Focus Adverse reactions
- 17 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 17 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 10 Jun 2017 Biomarkers information updated